Table 1. Summary of the clinical outcomes of esophageal GISTs from large case series studies.
| Studies | N | Study design | Age (mean) | Size (cm) (mean ± SD) | Surgery (n) | Adjuvant TKI | Recurrence (n) | 5-year-DFS (%) | 5-year-DSS (%) | 5-year-OS (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Nakano (21) | 153 | Literature review | 61.0 | 7.3±4.1 | 139 | – | 23 of 139 (local 5, distant 18) | 57.0% | – | 88.7% |
| Feng (20) | 135 | Literature review | 58.6 | 7.3±3.1 | 125 | (+) 38, (−) 95 | 22 of 97 | 65.1% | 65.9% | – |
| Lott (2) | 55 | Ulmer GIST registry, literature review | 60.3 | 8.0±4.8 | 33 (enucleation 14, esophagectomy 19) | (+) 6, (−) 49 | 14 of 55 | 65.3% | 50.9% | 48.3% |
| Kukar (54) | 29 | SEER database | 65.6 | – | 16 | – | 9 (disease specific death) | – | 65.0% | 88.7% |
| Kang (31) | 27 | Case series (multicenter) | 56.0 | 5.6±3.1 | 25 (enucleation 15, esophagectomy 10) | No adjuvant TKI | 9 of 22 (local 5, distant 4) | – | – | – |
TKI, thymidine kinase inhibitor; DFS, disease free survival; DSS, disease specific survival; OS, overall survival.